Paratek

The Biomedical Advanced Research and Development Authority, part of HHS, just announced an award as much as $285 million to Paratek, a publicly-owned Boston-based biopharmaceutical company that focuses on infectious disease research, to develop a new antibiotic for anthrax. But, will pull incentives – rewarding companies for the successful development of new antibiotics – be enough to keep large, private companies in the field of antibiotic research? ACSH advisor Dr. David Shlaes explains.